Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the best high short interest stocks with highest upside potential. On May 27, Madrigal presented new data at the 2026 EASL Congress, reinforcing ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra®(resmetirom) Analysis of two-year data in ...

Rezdiffra (resmetirom) has potential interactions with other medications. These interactions could affect how well the drug works or cause harmful effects. Rezdiffra is used in adults to treat ...

Axsome Therapeutics's stock has more than doubled in value over the past five years. The company owes that growth to solid clinical and commercial progress with its leading candidates, including ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Rezdiffra, the first FDA ...

Madrigal Pharmaceuticals is continuing to splash the cash this year on liver disease drugs it can combine with its own potential blockbuster Rezdiffra. Just weeks after betting $50 million on a DGAT2i ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of its Phase 3 MAESTRO-NAFLD-1 trial, showcasing the potential of Rezdiffra for ...

Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its approved liver disease med Rezdiffra. Madrigal’s thyroid hormone ...